https://charts.traderzeitung.de/phases/US00289Y2063 string(1419) "{"isin":"US00289Y2063","name":"Abeona Therapeutics Inc","stock_id_xnas":7873074,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.675,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":5.71,"close_at":"2026-09-22 13:19:00","complete":true,"perf_pct":0.6167},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.83,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":2.1016},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.525,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-5.2316},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Abeona Therapeutics Aktie News & Nachrichten

[WKN: A3DMHM | Symbol: ABEO]

Realtimekurs

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Abeona Therapeutics gefunden werden.

Abeona Therapeutics Nachrichtenticker öffnen

MT Newswires 16.09.2026 15:18 Uhr

Abeona Therapeutics Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Sektor-Update: Gesundheitsaktien legen vorbörslich am Mittwoch leicht zu

Abeona Therapeutics aktiviert 8. ZEVASKYN-Behandlungszentrum in Florida

Oppenheimer senkt Kursziel für Abeona Therapeutics von $22 auf $21 und belässt die Einstufung auf Outperform

Sektor-Update: Gesundheitsaktien am späten Nachmittag schwächer

Sektor-Update: Healthcare

Abeona Therapeutics Aktien fallen nach verfehlten Q2-Zahlen